PolyPid Posts Zero Revenue and Wider-Than-Expected Loss in Q3
PYPD sits 78% above its 52-week low of $3.5.
Summary
PolyPid reported a Q3 adjusted loss of 24 cents a share, missing the 6 cents of earnings five analysts expected, and revenue came in at zero versus an $18.00 million consensus. The quarterly net loss was $5.75 million. The miss is stark but not a surprise in kind: the company has no approved product revenue yet, and the story remains the D-PLEX100 EU marketing application now under EMA review after the October 1 validation, plus the November 28, 2026 PDUFA date for the U.S. filing. The October 1 mutual termination of the ADVANZ PHARMA European license returned commercialization rights to PolyPid, so the company is now carrying that launch burden itself. Shares are up 45.4% year to date and 19.7% this quarter, so the gap between zero revenue and a $12 median price target leaves little room for execution slippage.
At the time of this announcement, PYPD was trading at $6.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $128.2M. The 52-week trading range was $3.50 to $6.68. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.